ArticleEuropean radiology2025
Comparing three-dimensional zero echo time (3D-ZTE) lung MRI and chest CT in the evaluation of systemic sclerosis-related interstitial lung disease.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- Diagnostic accuracy of ultrashort echo times-MRI in patients with and without idiopathic pulmonary fibrosis.European radiology · 2026Article
- Optimized 3D UTE and ZTE MRI for high-resolution lung imaging: A comparative study.Magnetic resonance in medicine · 2026Article
- Magnetic Resonance Imaging in the Clinical Evaluation of Lung Disorders: Current Status and Future Prospects.Journal of magnetic resonance imaging : JMRI · 2025Review
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSystemic sclerosis (SSc) is a chronic disease that can cause interstitial lung disease (ILD), a poor prognostic factor in SSc patients. Given the concerns over radiation exposure from repeated CT scans, there is a growing interest in exploring radiation-free imaging alternatives like MRI for ILD evaluation. The aim of this study is to assess the efficacy of three-dimensional zero echo time (3D-ZTE) MRI in assessing SSc-related ILD compared to the thin-slice chest CT.
methodsThis prospective single-center study investigated 65 SSc patients. SSc patients underwent CT, 3D-ZTE lung MRI, and pulmonary function tests (PFTs) within a week. Three independent reviews visually quantified ILD extent on ZTE and CT imaging and the correlation of ILD extent with PFTs was analyzed. Statistical analyses were performed, including the intraclass correlation coefficient (ICC), Kruskal-Wallis tests, Bland-Altmann analysis, and correlation analyses between imaging results and PFTs.
resultsILD was detected in 45 patients via CT. 3D-ZTE MRI identified ILD in 41 (91.1%) of these cases, demonstrating a strong correlation with CT in assessing ILD severity (r = 0.986, p < 0.001). The median ILD extent scores were 5% for CT and 6% for 3D-ZTE MRI. Interobserver reliability for 3D-ZTE MRI was excellent, with ICC values ranging from 0.853 to 0.969. The analysis also revealed significant negative correlations between ILD extent on ZTE MRI and lung function, particularly FVC.
conclusion3D-ZTE lung MRI is a reliable and radiation-free alternative to chest CT for evaluating SSc-related ILD, with a strong correlation in assessing total fibrosis and ground-glass opacities, though limitations remain in detecting fine reticulations and coarseness. KEY POINTS: Question Can 3D-ZTE MRI replace thin-slice chest CT as a radiation-free method for assessing SSc-related ILD? Findings 3D-ZTE lung MRI showed an excellent agreement with thin-slice CT in evaluating ILD extent in SSc patients (r = 0.986, p < 0.001). Clinical relevance 3D-ZTE lung MRI provides a reliable, radiation-free alternative to CT for assessing ILD extent in SSc patients, ensuring safer longitudinal monitoring and management.
Indexed as
Identifiers
39592487What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.